These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 33991350)

  • 21. Safety, efficacy, and pharmacokinetics of bedaquiline in Japanese patients with pulmonary multidrug-resistant tuberculosis: An interim analysis of an open-label, phase 2 study.
    Tsuyuguchi K; Sasaki Y; Mitarai S; Kurosawa K; Saito Y; Koh T
    Respir Investig; 2019 Jul; 57(4):345-353. PubMed ID: 30745177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.
    Quinney SK; Zhang X; Lucksiri A; Gorski JC; Li L; Hall SD
    Drug Metab Dispos; 2010 Feb; 38(2):241-8. PubMed ID: 19884323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bedaquiline as Treatment for Disseminated Nontuberculous Mycobacteria Infection in 2 Patients Co-Infected with HIV.
    Gil E; Sweeney N; Barrett V; Morris-Jones S; Miller RF; Johnston VJ; Brown M
    Emerg Infect Dis; 2021 Mar; 27(3):944-948. PubMed ID: 33622490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection.
    Ferro BE; Srivastava S; Deshpande D; Pasipanodya JG; van Soolingen D; Mouton JW; van Ingen J; Gumbo T
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6374-6. PubMed ID: 27458221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
    Brill MJ; Svensson EM; Pandie M; Maartens G; Karlsson MO
    Int J Antimicrob Agents; 2017 Feb; 49(2):212-217. PubMed ID: 28038962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.
    Kakuda TN; Woodfall B; De Marez T; Peeters M; Vandermeulen K; Aharchi F; Hoetelmans RM
    J Antimicrob Chemother; 2014 Mar; 69(3):728-34. PubMed ID: 24155058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.
    Ruth MM; Sangen JJN; Remmers K; Pennings LJ; Svensson E; Aarnoutse RE; Zweijpfenning SMH; Hoefsloot W; Kuipers S; Magis-Escurra C; Wertheim HFL; van Ingen J
    J Antimicrob Chemother; 2019 Apr; 74(4):935-943. PubMed ID: 30649327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and tolerability of extended-release clarithromycin.
    Guay DR; Gustavson LE; Devcich KJ; Zhang J; Cao G; Olson CA
    Clin Ther; 2001 Apr; 23(4):566-77. PubMed ID: 11354390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
    Chahine EB; Karaoui LR; Mansour H
    Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study.
    Kaya F; Ernest JP; LoMauro K; Gengenbacher M; Madani A; Aragaw WW; Zimmerman MD; Sarathy JP; Alvarez N; Daudelin I; Wang H; Lanni F; Weiner DM; Via LE; Barry CE; Olivier KN; Dick T; Podell BK; Savic RM; Dartois V
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0221221. PubMed ID: 35099272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Portuguese in vitro antibiotic susceptibilities favor current nontuberculous mycobacteria treatment guidelines.
    Durão V; Silva A; Macedo R; Durão P; Santos-Silva A; Duarte R
    Pulmonology; 2019; 25(3):162-167. PubMed ID: 30309821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Nontuberculous mycobacteria in cystic fibrosis].
    Le Bourgeois M; Sermet-Gaudelus I; Catherinot E; Gaillard JL
    Arch Pediatr; 2005 Aug; 12 Suppl 2():S117-21. PubMed ID: 16129322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
    Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
    J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease.
    Yoon HY; Jo KW; Nam GB; Shim TS
    Int J Tuberc Lung Dis; 2017 Sep; 21(9):996-1001. PubMed ID: 28826448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects.
    Winter H; Egizi E; Murray S; Erondu N; Ginsberg A; Rouse DJ; Severynse-Stevens D; Pauli E
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1219-24. PubMed ID: 25512422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis.
    Svensson EM; Aweeka F; Park JG; Marzan F; Dooley KE; Karlsson MO
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2780-7. PubMed ID: 23571542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.
    Brown-Elliott BA; Nash KA; Wallace RJ
    Clin Microbiol Rev; 2012 Jul; 25(3):545-82. PubMed ID: 22763637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Svensson EM; Dooley KE; Karlsson MO
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6406-12. PubMed ID: 25114140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria.
    Brown-Elliott BA; Woods GL
    J Clin Microbiol; 2019 Oct; 57(10):. PubMed ID: 31315954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nontuberculous mycobacterial ocular infections--comparing the clinical and microbiological characteristics between Mycobacterium abscessus and Mycobacterium massiliense.
    Chu HS; Chang SC; Shen EP; Hu FR
    PLoS One; 2015; 10(1):e0116236. PubMed ID: 25581038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.